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after primary cytoreductive surgery and adjuvant doxorubicin and
ifosfamide chemotherapy.
Case presentation
A previously healthy 40-year-old woman presented to her primary
care physician with a several-month history of fatigue and nausea.
When her nausea did not respond to medical management, she was re-Introduction
Angiosarcomas are rare vascular tumors that comprise up to 3% of all
adult soft tissue sarcomas. Themajority of angiosarcomas occur in cuta-
neous sites, most frequently in the head and neck region. They can be
caused by prior radiation, chronic lymphedema, or a history of exposure
to vinyl-chloride chemotherapy (Bradford et al., 2010). Although
one-fourth of these tumors arise in deep soft tissue, angiosarcoma has
only rarely been described in the ovary. The ﬁrst reported case was in
1931 and, to date, less than 35 cases have been published in the litera-
ture (Bösmüller et al., 2011). Angiosarcomas, regardless of anatomic
site, demonstrate aggressive clinical behavior, with median survival
ranging from 15 to 30 months, and fewer than 12% of patients alive at
5 years (Penel et al., 2007).
In general, patients with ovarian angiosarcoma present with ad-
vanced disease and have a very poor prognosis. Among those patients
with FIGO stage III and IV disease, the median survival is 6 to 7 months,
with an overall range of 1 to 30 months (Bradford et al., 2010). Typically,
radical surgical excision is followed by any number of possible chemo-
therapeutic regimens. For metastatic soft-tissue sarcomas, anthracyclines
and ifosfamide have proven to be the most effective chemotherapeutic
agents. Additionally, taxanes have demonstrated promising results in
angiosarcomas of the head and neck (Penel et al., 2008). We report aGynecology and Reproductive
eet, ASB 1-3-078, Boston, MA
).
-ND license.ferred to a gastroenterologist. Upper endoscopy, colonoscopy, abdomi-
nal ultrasound, and HIDA (hepatobiliary iminodiacetic acid) scans
were non-diagnostic, but her nausea resolved spontaneously. Three
months later, she presented to a local community hospital emergency
department with rapidly increasing abdominal girth. CT (computed to-
mography) scan of the abdomen and pelvis revealed an 11×6 cmpelvic
mass, copious ascites, and omental nodularity. SerumCA125was elevat-
ed at 1851 U/mL (normal range, b35 U/mL). Due to the suspicion for
ovarian malignancy, she was transferred to our institution for gyneco-
logic oncology consultation.
She was counseled about primary cytoreductive surgery. At explor-
atory laparotomy, 5 L of chylous ascites was drained, omental caking
was noted, and a 15 cm right adnexal mass was seen with conﬂuent
tumor that coveredmost of thepelvic peritoneum. Intraoperative frozen
section of the right ovary and fallopian tube demonstrated a high-grade
spindle cell neoplasm. Surgery included abdominal hysterectomy, bilat-
eral salpingo-oophorectomy, omentectomy, appendectomy, ablation of
implants, en bloc resection of the rectosigmoidwith all surrounding pel-
vic peritoneum, and low pelvic anastomosis. No gross residual disease
was present at the completion of the procedure.
The patient was discharged home on day 7 after an uncomplicated
postoperative course. Four weeks after surgery, her CA125 had normal-
ized to 26 U/mL. Final pathology demonstrated an ovarian angiosarcoma
and chemotherapy was initiated. Doxorubicin (25 mg/m2) and
ifosfamide (2.5 g/m2) were administered on days 1–3 of a three-week
treatment cycle. Due to the risk of myelosuppression, pegﬁlgrastim
(6 mg) was routinely given on day 4. She completed six courses of ther-
apy with a single episode of neutropenic fever. A repeat CT scan of the
chest, abdomen and pelvis showed no evidence of disease and her
CA125 was 18 U/mL, thus she was presumed to be in clinical remission.
At a surveillance visit three months after completion of chemother-
apy, her CA125 was still within normal range (16 U/mL). Two months
24 S.H. Guseh et al. / Gynecologic Oncology Reports 4 (2013) 23–25later, she noted worsening abdominal discomfort that prompted a CT
scan of the abdomen and pelvis. She was noted to have
re-accumulation of ascites, peri-umbilical nodularity, and a 9 cm pelvic
mass, concerning for recurrent disease. Her CA125 had increased to
54 U/mL. Weekly paclitaxel at 80 mg/m2 was initiated and a partial re-
sponsewas observed. She currently has progressive disease, but retains
a good quality of life on palliative chemotherapy, 18 months after initial
surgery.
Pathology
On gross examination, the right ovary measured 15×11×2 cm and
weighed 400 g. The surface was predominantly smooth, tan to purple,
with foci of fresh hemorrhage. The tumor had a soft, nodular, bosselated
cut surface [Fig. 1, A]. Onmicroscopic examination, anastomosing vascu-
lar spaces with slit-like lumina were interspersed with solid fascicular
areas [Fig. 1, B–C]. Higher magniﬁcation demonstrated pleomorphic,Fig. 1. Ovarian angiosarcoma. (A). The tumor has a soft, spongy, and hemorrhagic cut surfac
with solid areas (C, magniﬁcation: ×100). (D) Higher magniﬁcation reveals the tumor cells
(magniﬁcation: ×200). (E) The tumor has areas with high grade, pleomorphic cytologic aty
and intracytoplasmic lumina (magniﬁcation: ×400). (F) Immunohistochemistry for CD31 repithelioid to focally spindled cells, somedisplaying intracytoplasmic lu-
mina [Fig. 1, D–E]. Brisk mitotic activity (>10 mitoses/10 high power
ﬁelds), necrosis, and hemorrhage were present. Immunohistochemical
studies showed strong positivity for CD31 and CD34 (vascular markers)
[Fig. 1, F], while keratin, EMA andWT-1were negative. Themorphologic
and immunohistochemicalﬁndings supported a diagnosis of spindle and
epithelioid angiosarcoma, grade 3 of 3, primary of the right ovary with
secondary involvement of uterine and appendiceal serosa, muscularis
propria of the rectosigmoid colon, and omentum (FIGO stage IIIC).
Comment
Ovarian angiosarcoma is an extremely rare tumor, with less than 35
cases reported in the literature (Bösmüller et al., 2011). Similar to the
more common epithelial ovarian cancers, angiosarcomas are associated
with non-speciﬁc symptoms and often present with advanced stage.
Ovarian angiosarcoma occurs in all age groups, with reported casese. On microscopic examination, anastomosing vascular spaces are seen (B) interspersed
to be epithelioid to focally spindled. Notice the presence of compressed, slit-like lumina
pia morphology associated with numerous mitotic ﬁgures, including atypical mitoses,
eveals diffuse strong tumor positivity, (magniﬁcation: ×100).
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age of 37 (Bösmüller et al., 2011).
Angiosarcomas are malignant and inﬁltrative vascular tumors.
They can be pure or part of mixed malignant müllerian tumors,
adenosarcomas, teratomas, or surface epithelial tumors. Histological-
ly, they range from well- to poorly-differentiated. Well-differentiated
angiosarcomas demonstrate more organization as they are often
comprised of well-formed vascular spaces. In contrast, poorly-
differentiated angiosarcomas, as found in our patient, may be a diag-
nostic challenge as organizational architecture devolves and cellular
atypia rises. The differential diagnosis includes poorly-differentiated
carcinoma, other more common sarcomas such as leiomyosarcoma,
adenosarcoma with sarcomatous overgrowth, carcinosarcoma, or
even malignant melanoma, yolk sac tumor, and choriocarcinoma.
Metastatic lesions, including metastatic angiosarcoma, must be
ruled out (Bösmüller et al., 2011; Young et al., 2010). Immunohisto-
chemical analysis may be helpful to establish a diagnosis of
angiosarcoma. Immunohistochemical studies commonly used to in-
clude vascular markers, more commonly CD34 and CD31 (Young et
al., 2010).
Once accurately diagnosed, management of ovarian angiosarcoma
is largely by extrapolation, as this is a very unusual tumor in the
ovary. Unlike previous reports (Bradford et al., 2010), our patient
had a complete response to therapy with extended survival, which
presumably, was due to a combination of her initial radical
debulking surgery and the aggressive adjuvant chemotherapy
regimen. Doxorubicin is an anthracycline that is commonly used
for soft tissue sarcomas, including angiosarcomas, yielding objective
response rates of 20 to 30% in advanced disease (Eriksson, 2010).
The mustard alkylating agent, ifosfamide, is the only other agent
with comparable response rates (Eriksson, 2010; Penel et al.,
2011). Numerous trials in the soft-tissue sarcoma population have
investigated doxorubicin and ifosfamide combination therapy. The
dual regimen appears to demonstrate a synergistic effect with
tumor response rates of up to 50%, but with greater toxicity (Penel
et al., 2007; Eriksson, 2010; Quesenberry et al., 2005). Using
pegﬁlgrastim to lessen bone marrow suppression, our patient toler-
ated the regimen very well.Taxanes are generally considered non-effective in the treatment of
soft-tissue sarcomas, with the exception of angiosarcoma. Speciﬁcally,
paclitaxel has been shown to be active against the vascular-derived
Kaposi's sarcoma and, more recently, cutaneous angiosarcoma of the
head and neck (Penel et al., 2007, 2008, 2011; Eriksson, 2010). Weekly
low-dose administration increases the anti-angiogenic effect and dose
intensity, without signiﬁcantly increasing the toxicity proﬁle. The
anti-angiogenic activity is particularly potent in angiosarcomas, which
have been shown to overexpress pro-angiogenic factors, including
VEGF, ﬂt-1, ﬂk1, and ets-1 (Penel et al., 2007; Young et al., 2010).
Sorafenib, imatinib, bevacizumab or other novel anti-angiogenic biologic
molecules are currently under investigation and have also shown some
response against angiosarcomas (Penel et al., 2011). These small mole-
cules may play a future therapeutic role in targeting the signaling path-
ways associated with excess vascular proliferation and tumor growth.
In summary, aggressive cytoreduction to no gross residual use
paired with the novel use of paclitaxel has resulted in a sustained par-
tial response for our patient.
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